Industry-Sponsored Research Week
University-Industry Engagement Advisor

McMaster U inks research agreement around cannabinoids for chronic pain treatment

By David Schwartz
Published: September 11th, 2018

In the wake of legalization of marijuana in Canada, a bumper crop of research agreements are being signed to study the medicinal use of cannabinoids, and a deal between CannTrust Holdings Inc. McMaster University is the latest example.

CannTrust will be working with McMaster’s Michael G. DeGroote Pain Clinic of Hamilton Health Sciences and the Michael G. DeGroote Institute for Pain Research and Care on a range of randomized, placebo-controlled clinical trials in the first such partnership between the company and a Canadian University.

The first clinical trial, Cannabis Oil for Chronic Non-Cancer Pain Treatment (CONCEPT), is expected to begin this fall, with additional studies to follow.

The results will be aimed at designing more effective, safer treatment protocols for cannabinoid use in medicine and developing public health policies.

An analysis of CannTrust’s 48,000 existing customer profiles indicates that pain is one of the primary reasons for utilizing medical cannabis, highlighting the need for trials in this area. Through research at the university, CannTrust hopes to help healthcare professionals and patients better understand the possible benefits of medical cannabis for those living with pain-related conditions and beyond.

“We are honoured to begin this partnership as our organizations share very similar values. Also, it further advances our participation in research, innovation and customer education. We feel privileged by the role CannTrust can play in supporting these world-class researchers advance the understanding of medical cannabis,” says Eric Paul, CEO of CannTrust.

Principal investigator for the study is Dr. Ramesh Zacharias, medical director of the Michael G. DeGroote Pain Clinic. “CannTrust is an excellent partner for our research due to its consistent quality, standardized products and scientific approach. For research studies, we demand this same precision and attention to detail, so we appreciate that CannTrust is supporting the critical work conducted by our Centre,” Zacharias said.

Earlier this summer, CannTrust announced an ALS clinical trial with Australia’s Gold Coast University Hospital. This new partnership with McMaster and Hamilton Health Sciences demonstrates the Company’s further commitment to support research and innovation to develop safe and effective cannabinoid dosage forms. The company is currently in discussions with other scientific partners on upcoming research projects.

Source: PR Newswire

Posted under: University-Industry Engagement Week

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment